Intervention Review

Risperidone in long-term treatment for bipolar disorder

  1. Jennifer M Rendell*,
  2. John Geddes

Editorial Group: Cochrane Depression, Anxiety and Neurosis Group

Published Online: 18 OCT 2006

Assessed as up-to-date: 21 AUG 2006

DOI: 10.1002/14651858.CD004999.pub2


How to Cite

Rendell JM, Geddes J. Risperidone in long-term treatment for bipolar disorder. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004999. DOI: 10.1002/14651858.CD004999.pub2.

Author Information

  1. University of Oxford, Department of Psychiatry, Oxford, UK

*Jennifer M Rendell, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, OX3 7JX, UK. jennifer.rendell@psych.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 OCT 2006

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Risperidone, an atypical antipsychotic, is used to treat acute manic episodes, particularly when psychotic symptoms are present. Drugs used to treat mania are often continued as long-term treatment to prevent relapse. There is a need for evidence of the effectiveness and safety of risperidone as long-term treatment.

Objectives

To assess the randomised evidence for the efficacy and tolerability of risperidone compared with placebo or other active pharmacological treatments as long-term treatment for prevention or attenuation of further episodes of mood disorder in patients with bipolar disorder.

Search methods

The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies) was search on 12/10/2005, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO were searched in October 2005. Reference lists and English language textbooks were searched; researchers in the field were contacted.

Selection criteria

Randomised trials comparing risperidone with placebo or other drug in long-term treatment for prevention of depressive or manic relapses.

Data collection and analysis

Not applicable.

Main results

No randomised trials comparing risperidone with other treatments for the prevention of manic and depressive relapses were identified.

Authors' conclusions

There is a need for randomised controlled trials comparing risperidone and other treatments for the prevention of relapse in bipolar disorder. The trials should involve randomisation of treatment for relapse prevention and involve long-term follow up.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Risperidone in the long-term treatment for bipolar disorder

No studies involving risperidone were identified which randomly assigned treatment for long-term relapse prevention. Trials involving random assignment of risperidone and other treatments for long-term treatment are needed.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

Risperidone在長期治療雙極性疾患上的效果

Risperidone,一種非典型抗精神病藥物,被用來治療急性躁症發作特別是有精神症狀時. 藥物治療躁症通常持續為長期治療來防止復發. Risperidone在作為長期治療雙極性疾患上的效果和安全性的證據是必須的.

目標

評估risperidone和安慰劑或是其他現行藥物治療作為於雙極性疾患的病患防止或是減弱未來情感疾患發作的長期治療之效能與耐受性的比較.

搜尋策略

The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTRStudies)於12/10/2005被搜尋, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO於2005年十月被搜尋. 參考文獻列表與英文語文的教科書被搜尋;聯絡了這個領域的研究者.

選擇標準

比較risperidone和安慰劑或是其他藥物在防止憂鬱或是躁症復發的隨機試驗

資料收集與分析

無可用資料

主要結論

沒有發現比較risperidone和其他治療來防止躁症和憂鬱復發的隨機試驗.

作者結論

比較risperidone和其他治療來防止雙極性疾患復發的隨機對照試驗是需要的. 試驗需與隨機治療防止復發和長期追蹤相關.

翻譯人

本摘要由彰化基督教醫院王智仁翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

沒有和risperidone被設計為長期防止復發的相關研究被發現. 以risperidone和其他治療作為長期治療的隨機分配試驗是需要的.